1 June 2021 in Molecular Therapy - Methods & Clinical Development
Clinical application of somatic genome editing requires therapeutics that are generalizable to a broad range of patients. Targeted insertion of promoterless transgenes can ensure that edits are permanent and broadly applicable while minimizing risks of off-target integration. In the liver, the Albumin (Alb) locus is currently the only well-characterized site for promoterless transgene insertion. Here, we target the Apoa1 locus with adeno-associated viral (AAV) delivery of CRISPR-Cas9 and achieve rates of 6% to 16% of targeted hepatocytes, with no evidence of toxicity. We further show that the endogenous Apoa1 promoter can drive robust and sustained expression of therapeutic proteins, such as apolipoprotein E (APOE), dramatically reducing plasma lipids in a model of hypercholesterolemia. Finally, we demonstrate that Apoa1-targeted fumarylacetoacetate hydrolase (FAH) can correct and rescue the severe metabolic liver disease hereditary tyrosinemia type I. In summary, we identify and validate Apoa1 as a novel integration site that supports durable transgene expression in the liver for gene therapy applications.
1 January 2026 in BMJ Open Quality
The American Diabetes Association has declared continuous glucose monitoring (CGM) use to be the standard of care in patients with diabetes mellitus (DM) on insulin. While primary care providers (PCPs) manage most patients with DM, the adoption of CGMs in the primary care setting remains significantly lower than in endocrinology practices. PCPs have reported education, insurance authorisation and challenges of a PCP environment as significant barriers to CGM use. Our project sought to increase CGM prescriptions at our academic primary care clinic by creating tools to address these barriers. This is a single-centre quality improvement study at our academic primary care practice with the aim to increase CGM prescriptions in our patients with DM prescribed insulin, excluding patients seen by the endocrinology department. Three interventions were introduced over a 10-month period: (1) an educational pamphlet detailing insurance coverage, ordering and documentation requirements, (2) electronic health record tools to aid in ordering and documentation and (3) a didactic session focused on CGM data interpretation. The number of CGM prescriptions beginning August 2024 was reported monthly. Provider comfort with CGM prescription and data interpretation was assessed using a Likert scale of 1–5 (5 being the most comfortable). Following all three interventions, CGM prescriptions increased by 6.6%. On survey, providers reported improvements in correctly prescribing CGMs and comfort in interpreting CGM data. Referrals to endocrinology for type 2 DM also decreased by 25.3%. Despite known benefits of use in DM care, CGMs are underused in the primary care setting. Provider education and tools led to an increase in CGM prescriptions and improved PCP comfort with CGM use. These interventions demonstrate an effective way to address key barriers to CGM use in primary care.
20 February 2025 in American Journal of Case Reports
BACKGROUND Adrenocorticotrophic hormone (ACTH)-secreting pancreatic neuroendocrine tumors (pNETs) are rare and poorly understood entities. Only 1-2% of pancreatic neoplasms are pNETs, and even fewer are hormone-secreting. They can present indolently or with overt Cushing syndrome. Their diagnosis involves complex multi-modal imaging and laboratory evaluation. Management includes medications, such as somatostatin analogs and ketoconazole, as well as surgical resection for definitive treatment. This report describes a 46-year-old woman who presented with overt Cushing syndrome and was ultimately diagnosed with a pNET. CASE REPORT This patient's initial symptoms and laboratory testing were consistent with Cushing syndrome. A high-dose dexamethasone suppression test suggested ectopic ACTH production, and magnetic resonance imaging (MRI) of the brain showed a pituitary microadenoma. However, computed tomography (CT) of the abdomen and endoscopic ultrasound-guided biopsy with immunohistochemistry confirmed a pancreatic mass as the source of ACTH production with potential hepatic metastasis. Her Cushing syndrome was managed with ketoconazole and octreotide. Subsequently, >99% of the pNET was surgically removed, resulting in reversal of her Cushing syndrome. Currently, she is being monitored closely for recurrence. CONCLUSIONS Our management of this ACTH-secreting pNET highlights the complexities of diagnosis and multidisciplinary treatment options, which are underrepresented in the current literature on this rare entity. This case emphasizes the challenges in evaluation, including the importance of early and precise diagnosis in the face of potential confounders.